Considerations for the clinical development of immuno-oncology agents in cancer

Targeting of the immune system has shown to be a successful therapeutic approach in cancer, with the development of check point inhibitors (ICI) or T-cell engagers (TCE). As immuno-oncology agents modulate the immune system to attack cancer cells and do not act directly on oncogenic vulnerabilities,...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandiella, Atanasio, Calvo, Emiliano, Moreno, Victor, Amir, Eitan, Templeton, Arnoud, Ocana, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451075/
https://www.ncbi.nlm.nih.gov/pubmed/37638048
http://dx.doi.org/10.3389/fimmu.2023.1229575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451075/
https://www.ncbi.nlm.nih.gov/pubmed/37638048
http://dx.doi.org/10.3389/fimmu.2023.1229575

Ejemplares similares